
Triplet therapy including belamaf prolongs survival in multiple myeloma
A study presented during the February 2024 session of the American Society for Clinical Oncology Plenary Series shows that triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone significantly improves outcomes for patients with relapsed or refractory multiple myeloma (RRMM), with an acceptable safety profile. The trial found that the median progression-free survival (PFS)…